Biological
Adacel clinical trials
- studies test it
- 28
- open now
- 0
- in phase 3
- 10
- first study started
- 2005
How studies write it
Studies that test it under each name
Studies by the year they started
28 studies that test it; most in 2006 (6)
| Year | Studies |
|---|---|
| 2005 | 2 |
| 2006 | 6 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 4
- Phase 3
- 10
- Phase 4
- 14
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 22 · Other 6
Sanofi Pasteur, a Sanofi Company (15) · Sanofi (3) · Merck Sharp & Dohme LLC (2) · Farzanah Laher (1) · Centre Hospitalier Universitaire Saint Pierre (1) · GCAM Inc. (1) · Dalhousie University (1) · GlaxoSmithKline (1)
Often tested with
Tested in the same studies.
Meningococcal Vaccines (4) · Boostrix (2) · Vaxelis (1) · Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (1)
Studies
Open first, then newest update. How each study uses adacel is read from its arms, and is right about nine times in ten.
Testing it · 28
- Pertussis Vaccination Among HIV-infected and HIV-uninfected Pregnant WomenCompletedPhase 4Farzanah LaherNCT05264662Written as Adacel (Tdap)
- Maternal Determinants of Infant Immunity to PertussisCompletedPhase 4Centre Hospitalier Universitaire Saint PierreNCT05856396Written as Triaxis® (Pertussis-containing vaccine)
- Tdap Vaccine Safety for Plasma DonorsCompletedPhase 2/3GCAM Inc.NCT04142983Written as Adacel
- Post Marketing Surveillance for ADACEL™ in South KoreaCompletedPhase 4Sanofi Pasteur, a Sanofi CompanyNCT01137435Written as ADACEL™:Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined
- Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy AdolescentsCompletedPhase 2Sanofi Pasteur, a Sanofi CompanyNCT02199691Written as Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed
- Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy SubjectsTerminatedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT02992418Written as Tdap: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine adsorbed
- Adacel® Booster Vaccination for CMI Assay DevelopmentCompletedPhase 4Dalhousie UniversityNCT04543669Written as Adacel®
- A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)CompletedPhase 3Merck Sharp & Dohme LLCNCT00988884Written as Comparator: Adacel™ (Concomitant)
- Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 YearsCompletedPhase 3GlaxoSmithKlineNCT00346073Written as ADACEL®
- Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years OldCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT02089347Written as Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed
- A Study to Assess the Safety of Adacel® VaccineCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT01040052Written as Adacel® (Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis)
- Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis VaccineCompletedPhase 4Sanofi Pasteur, a Sanofi CompanyNCT00304265Written as COVAXIS™: Tetanus, diphtheria, acellular 5-component pertussis, or + inactivated poliovirus vaccine (REPEVAX®)
- Immunogenicity and Safety of ADACEL™ as Fifth Dose in TaiwanCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT00258908Written as Diphteria, tetanus, and Acellular Pertussis vaccine
- Study of Adacel® Vaccine Administered to Persons 10 Years of AgeCompletedPhase 4SanofiNCT01311557Written as Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed
- Study of the Tdap Combined Vaccine (ADACEL™) as a Booster Dose in Healthy Adults and Children in ChinaCompletedPhase 1Sanofi Pasteur, a Sanofi CompanyNCT01933776Written as Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap
- Immunogenicity of Adacel® and BOOSTRIX® Vaccines in AdolescentsCompletedPhase 4Sanofi Pasteur, a Sanofi CompanyNCT01629589Written as Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®)
- Sanofi Pasteur's Tdap Combined Vaccine as a Booster Versus Local DT Vaccine in Children or Versus Local Td Vaccine in Adolescents and Adults in China.CompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT01993173Written as Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap (ADACEL)
- Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)CompletedPhase 3Merck Sharp & Dohme LLCNCT00325130Written as Comparator: Adacel™ (Concomitant)
- Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous DoseCompletedPhase 4Sanofi Pasteur, a Sanofi CompanyNCT00712959Written as Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)
- Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in AdolescentsCompletedPhase 1/2Sanofi Pasteur, a Sanofi CompanyNCT01689324Written as (ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis
See all 28 studies that test adacel →
As the comparator · 2 — what is tested is compared with adacel
- Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9CompletedPhase 3GlaxoSmithKlineNCT00489970Written as Adacel
- Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South KoreaCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT01642589Written as Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed